LNSR at a glance
LENSAR, Inc. (LNSR, SEC CIK 1320350) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LENSAR, Inc. (LNSR) reported revenue of $51.7 million (up 12.4% from FY2024) and a net loss of $34.3 million. Diluted EPS was -$2.87.
- As of September 30, 2026, 14 institutional investment managers tracked by SignalX reported holding LENSAR, Inc. (LNSR) shares worth $6.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by O'Farrell Elizabeth G. on November 18, 2026 of 10,961 shares at $4.97 per share.
- In the last 90 days, LNSR insiders reported 0 open-market purchases ($0) and 2 open-market sales ($170K) on Form 4, a net sale of $170K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $51.7M
- +12.4% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$170K
- 13F holders
- 14 funds
- $6.6M · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New legal risk, triggered by terminated Alcon merger: additional shareholder demands or litigation could increase costs and result in damages
- Most material update, merger termination: distributor activity declined after announcement, with further production and inventory impacts expected
- Regulatory risk, EU Medical Devices Regulation: CE-mark compliance required before selling products in EU member states
- Competitive risk, Bausch + Lomb SeeLyra™: second-generation femtosecond laser expected to launch in the second half of 2026
- Financial risk, credit facility: $3.0 million minimum cash requirement until 2026 EBITDA covenant compliance
Management Discussion & Analysis
- Revenue $14.1M, down 1% YoY from $14.3M, driven by lower System sales offset by higher procedure volume
- Product revenue $10.7M, down 6%; procedure revenue $9.2M, up 17% from $7.8M
- Gross margin 57.8% vs 42.1% YoY, based on revenue and cost of revenue
- Net loss $4.7M vs $3.7M; Adjusted EBITDA $1.7M vs $(0.3)M
- Operating cash outflow $5.3M vs $15.4M; $10.0M revolving facility established, undrawn at quarter-end; tariff inflation remains a headwind
AI summary of the LNSR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced by LENSAR
- Press release contains the financial figures and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $14.1M, down 1% year over year, reflecting lower system sales and seasonal purchasing patterns
- Recurring revenue $12.6M, up 17%, reaching 89% of revenue versus 75% a year earlier
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results announced August 13, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $16.5M, up 18%, with recurring revenue $13.7M, up 20%, strengthening the recurring-revenue model
- 10 ALLY placements, 13-system backlog, and 215 ALLY systems installed, up 30% year over year
Item 5.07: Submission of Matters to a Vote of Security Holders
- 90.53% voting participation, providing strong shareholder representation at the August 4 annual meeting
- Three Class III directors elected through 2029, preserving board continuity
AI summaries of LNSR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LNSR
Don't miss the next LNSR filing
- Alerts as it files. A push when LNSR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LNSR, by share count.
- Ask anything. An AI agent that reads every LNSR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Farrell Elizabeth G. | M | Nov 18, 2026 | 10,961 | - |
| O'Farrell Elizabeth G. | Sell | Nov 18, 2026 | 10,961 | $4.97 |
| O'Farrell Elizabeth G. | M | Nov 18, 2026 | 10,961 | $3.23 |
| O'Farrell Elizabeth G. | M | Nov 17, 2026 | 22,214 | $3.23 |
| O'Farrell Elizabeth G. | M | Nov 17, 2026 | 22,214 | - |
| O'Farrell Elizabeth G. | Sell | Nov 17, 2026 | 22,214 | $5.20 |
| Winer Gary M | A | Nov 11, 2026 | 4,169 | $4.53 |
| WEISNER AIMEE S | A | Jun 3, 2026 | 17,421 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $35.7M | $46.0M | $51.7M |
| Operating Income | - | -$10.7M | -$24.6M |
| Net Income | -$14.4M | -$31.4M | -$34.3M |
| Op. Margin | - | -23.2% | -47.6% |
| Net Margin | -40.3% | -68.3% | -66.4% |
| Balance Sheet | |||
| Total Assets | - | $66.3M | $71.4M |
| Equity | - | $4.9M | -$26.0M |
| ROE | - | -645.9% | 131.7% |
| Per Share | |||
| EPS | $-1.31 | $-2.73 | $-2.87 |
| Cash Flow | |||
| Operating CF | - | -$2.3M | -$14.8M |
| CapEx | $236K | $156K | $83K |
Source: XBRL data in LENSAR, Inc. (LNSR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LNSR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 14 | $6.6M |
| Q2 2026 | 15 | $6.2M |
| Q1 2026 | 15 | $10.1M |
| Q4 2025 | 13 | $20.3M |
| Q3 2025 | 15 | $20.9M |
| Q2 2025 | 17 | $21.6M |
| Q1 2025 | 13 | $21.4M |
| Q4 2024 | 7 | $13.4M |
- Citadel Advisors LLC+35.5K (+99%)
- Morgan Stanley+19.6K (+231%)
- JPMorgan Chase & Co+1.1K (+255%)
- Dimensional Fund Advisors−78.7K (-52%)
- Millennium Management−32.5K (-27%)
- BlackRock−18.6K (-10%)
- Goldman Sachs Group−10.4K (-17%)
- State Street Corp−9.0K (-11%)
- BNY Mellon−10.1K
- FMR LLC (Fidelity)−3.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 109 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LNSR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
LNSR SEC filings: frequently asked questions
Are LNSR insiders buying or selling?
In the last 90 days, LENSAR, Inc. (LNSR) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $169,989 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LNSR stock?
As of September 30, 2026, the largest LENSAR, Inc. (LNSR) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.7 million), BlackRock ($1.1 million), Millennium Management ($581,000), Dimensional Fund Advisors ($480,000), State Street Corp ($474,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LNSR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LENSAR, Inc. (LNSR) reported revenue of $51.7 million (up 12.4% from FY2024) and a net loss of $34.3 million. Diluted EPS was -$2.87. The figures come from the XBRL data in the 10-K.
What did LNSR report in its latest 8-K?
LENSAR, Inc. (LNSR) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced by LENSAR.
What are the latest LNSR SEC filings?
LENSAR, Inc. (LNSR) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.
What is LNSR's SEC CIK number?
LENSAR, Inc. (LNSR)'s SEC Central Index Key (CIK) is 1320350. EDGAR lists every LNSR filing under that number.
Ask anything about LNSR
The research agent reads LNSR's filings, financials, insider trades and 13F holders, then answers with sources.